{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:59:48Z","timestamp":1763564388029,"version":"3.38.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research","award":["20K07594"],"award-info":[{"award-number":["20K07594"]}]},{"name":"JST SPRING","award":["JPMJSP2127 (to XY.W.)"],"award-info":[{"award-number":["JPMJSP2127 (to XY.W.)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00535-024-02180-1","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T18:20:03Z","timestamp":1731954003000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["YAP acts as an independent prognostic marker and regulates growth and metastasis of gastrointestinal stromal tumors via FBXW7-YAP pathway"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-6703","authenticated-orcid":false,"given":"Xiyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiliyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kosumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-4618","authenticated-orcid":false,"given":"Masaaki","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"2180_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K Soreide","year":"2016","unstructured":"Soreide K, Sandvik OM, Soreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39\u201346. https:\/\/doi.org\/10.1016\/j.canep.2015.10.031.","journal-title":"Cancer Epidemiol"},{"key":"2180_CR2","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26:5078\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1706.","journal-title":"Clin Cancer Res"},{"key":"2180_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","volume":"231","author":"RP DeMatteo","year":"2000","unstructured":"DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51\u20138. https:\/\/doi.org\/10.1097\/00000658-200001000-00008.","journal-title":"Ann Surg"},{"key":"2180_CR4","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.6004\/jnccn.2020.0058","volume":"18","author":"M von Mehren","year":"2020","unstructured":"von Mehren M, Kane JM, Bui MM, et al. NCCN guidelines insights: soft tissue sarcoma, Version 1.2021. J Natl Compr Cancer Netw. 2020;18:1604\u201312. https:\/\/doi.org\/10.6004\/jnccn.2020.0058.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2180_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:20\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.005.","journal-title":"Ann Oncol"},{"key":"2180_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265\u201372. https:\/\/doi.org\/10.1001\/jama.2012.347.","journal-title":"JAMA"},{"key":"2180_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","volume":"6","author":"E Wardelmann","year":"2005","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6:249\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(05)70097-8.","journal-title":"Lancet Oncol"},{"key":"2180_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865\u201378. https:\/\/doi.org\/10.1038\/nrc3143.","journal-title":"Nat Rev Cancer"},{"key":"2180_CR9","doi-asserted-by":"publisher","first-page":"12405","DOI":"10.1073\/pnas.0605579103","volume":"103","author":"M Overholtzer","year":"2006","unstructured":"Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006;103:12405\u201310. https:\/\/doi.org\/10.1073\/pnas.0605579103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2180_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.331546.119","volume":"34","author":"JH Koo","year":"2020","unstructured":"Koo JH, Plouffe SW, Meng Z, et al. Induction of AP-1 by YAP\/TAZ contributes to cell proliferation and organ growth. Genes Dev. 2020;34:72\u201386. https:\/\/doi.org\/10.1101\/gad.331546.119.","journal-title":"Genes Dev"},{"key":"2180_CR11","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1038\/s41388-019-0894-3","volume":"38","author":"WB Ou","year":"2019","unstructured":"Ou WB, Ni N, Zuo R, et al. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019;38:6615\u201329. https:\/\/doi.org\/10.1038\/s41388-019-0894-3.","journal-title":"Oncogene"},{"key":"2180_CR12","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-14-2191","volume":"21","author":"S Song","year":"2015","unstructured":"Song S, Honjo S, Jin J, et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21:2580\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2191.","journal-title":"Clin Cancer Res"},{"key":"2180_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ng.3228","volume":"47","author":"A Keren-Paz","year":"2015","unstructured":"Keren-Paz A, Emmanuel R, Samuels Y. YAP and the drug resistance highway. Nat Genet. 2015;47:193\u20134. https:\/\/doi.org\/10.1038\/ng.3228.","journal-title":"Nat Genet"},{"key":"2180_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin L, Sabnis AJ, Chan E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47:250\u20136. https:\/\/doi.org\/10.1038\/ng.3218.","journal-title":"Nat Genet"},{"key":"2180_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.686874","volume":"12","author":"T Chen","year":"2021","unstructured":"Chen T, Ni N, Yuan L, et al. Proteasome inhibition suppresses KIT-independent gastrointestinal stromal tumors via targeting Hippo\/YAP\/cyclin D1 signaling. Front Pharmacol. 2021;12: 686874. https:\/\/doi.org\/10.3389\/fphar.2021.686874.","journal-title":"Front Pharmacol"},{"key":"2180_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1126\/science.1065203","volume":"294","author":"DM Koepp","year":"2001","unstructured":"Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001;294:173\u20137. https:\/\/doi.org\/10.1126\/science.1065203.","journal-title":"Science"},{"key":"2180_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrc1881","volume":"6","author":"KI Nakayama","year":"2006","unstructured":"Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369\u201381. https:\/\/doi.org\/10.1038\/nrc1881.","journal-title":"Nat Rev Cancer"},{"key":"2180_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1476-4598-13-110","volume":"13","author":"K Tu","year":"2014","unstructured":"Tu K, Yang W, Li C, et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014;13:110. https:\/\/doi.org\/10.1186\/1476-4598-13-110.","journal-title":"Mol Cancer"},{"key":"2180_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","volume":"71","author":"J Wang","year":"2019","unstructured":"Wang J, Wang H, Peters M, et al. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol. 2019;71:742\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.027.","journal-title":"J Hepatol"},{"issue":"137\u201350","key":"2180_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.018","volume":"33","author":"KK Huang","year":"2018","unstructured":"Huang KK, Ramnarayanan K, Zhu F, et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33(137\u201350): e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.11.018.","journal-title":"Cancer Cell"},{"key":"2180_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10120-019-00950-y","volume":"22","author":"Y Koga","year":"2019","unstructured":"Koga Y, Iwatsuki M, Yamashita K, et al. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019;22:1100\u20138. https:\/\/doi.org\/10.1007\/s10120-019-00950-y.","journal-title":"Gastric Cancer"},{"key":"2180_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10120-023-01454-6","volume":"27","author":"X Wu","year":"2024","unstructured":"Wu X, Iwatsuki M, Takaki M, et al. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1. Gastric Cancer. 2024;27:235\u201347. https:\/\/doi.org\/10.1007\/s10120-023-01454-6.","journal-title":"Gastric Cancer"},{"key":"2180_CR23","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/ijc.34461","volume":"152","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Takahashi T, Obata Y, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. Int J Cancer. 2023;152:2580\u201393. https:\/\/doi.org\/10.1002\/ijc.34461.","journal-title":"Int J Cancer"},{"key":"2180_CR24","unstructured":"Therneau T. A package for survival analysis in S. R package version. 2015;2:2014."},{"key":"2180_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","volume":"130","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466\u201378. https:\/\/doi.org\/10.5858\/2006-130-1466-GSTROM.","journal-title":"Arch Pathol Lab Med"},{"key":"2180_CR26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/annonc\/mdr622","volume":"23","author":"JY Blay","year":"2012","unstructured":"Blay JY, Perol D, Le Cesne A. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Ann Oncol. 2012;23:1659\u201365. https:\/\/doi.org\/10.1093\/annonc\/mdr622.","journal-title":"Ann Oncol"},{"key":"2180_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"Azzolin L, Panciera T, Soligo S, et al. YAP\/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157\u201370. https:\/\/doi.org\/10.1016\/j.cell.2014.06.013.","journal-title":"Cell"},{"key":"2180_CR28","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park HW, Kim YC, Yu B, et al. Alternative Wnt signaling activates YAP\/TAZ. Cell. 2015;162:780\u201394. https:\/\/doi.org\/10.1016\/j.cell.2015.07.013.","journal-title":"Cell"},{"key":"2180_CR29","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","volume":"150","author":"FX Yu","year":"2012","unstructured":"Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780\u201391. https:\/\/doi.org\/10.1016\/j.cell.2012.06.037.","journal-title":"Cell"},{"key":"2180_CR30","doi-asserted-by":"publisher","first-page":"13461","DOI":"10.1074\/jbc.M113.529115","volume":"289","author":"SE Hiemer","year":"2014","unstructured":"Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem. 2014;289:13461\u201374. https:\/\/doi.org\/10.1074\/jbc.M113.529115.","journal-title":"J Biol Chem"},{"key":"2180_CR31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41416-022-02106-9","volume":"128","author":"Z Liu","year":"2023","unstructured":"Liu Z, Hayashi H, Matsumura K, et al. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP\/TAZ-Hedgehog signalling axis in pancreatic cancer. Br J Cancer. 2023;128:844\u201356. https:\/\/doi.org\/10.1038\/s41416-022-02106-9.","journal-title":"Br J Cancer"},{"key":"2180_CR32","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1002\/cncr.24495","volume":"115","author":"MZ Xu","year":"2009","unstructured":"Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576\u201385. https:\/\/doi.org\/10.1002\/cncr.24495.","journal-title":"Cancer"},{"key":"2180_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","volume":"5","author":"CDK Nguyen","year":"2019","unstructured":"Nguyen CDK, Yi C. YAP\/TAZ signaling and resistance to cancer therapy. Trends Cancer. 2019;5:283\u201396. https:\/\/doi.org\/10.1016\/j.trecan.2019.02.010.","journal-title":"Trends Cancer"},{"key":"2180_CR34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/neuonc\/noab244","volume":"24","author":"AM Barrette","year":"2022","unstructured":"Barrette AM, Ronk H, Joshi T, et al. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 2022;24:694\u2013707. https:\/\/doi.org\/10.1093\/neuonc\/noab244.","journal-title":"Neuro Oncol"},{"key":"2180_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-pathol-042220-021510","volume":"17","author":"JK Dermawan","year":"2022","unstructured":"Dermawan JK, Rubin BP. Molecular pathogenesis of gastrointestinal stromal tumor: a paradigm for personalized medicine. Annu Rev Pathol. 2022;17:323\u201344. https:\/\/doi.org\/10.1146\/annurev-pathol-042220-021510.","journal-title":"Annu Rev Pathol"},{"key":"2180_CR36","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1136\/gutjnl-2020-321175","volume":"70","author":"S Song","year":"2021","unstructured":"Song S, Chen Q, Li Y, et al. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021;70:2238\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2020-321175.","journal-title":"Gut"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02180-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02180-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02180-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:16:07Z","timestamp":1741086967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02180-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2180"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02180-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval of this study was granted by the ethics committee at Kumamoto University Hospital (approval numbers: 2143) The study was conducted in accordance with the Declaration of Helsinki principles.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}